223 related articles for article (PubMed ID: 17256836)
1. Discovery of a potent, selective, and orally active human epidermal growth factor receptor-2 sheddase inhibitor for the treatment of cancer.
Yao W; Zhuo J; Burns DM; Xu M; Zhang C; Li YL; Qian DQ; He C; Weng L; Shi E; Lin Q; Agrios C; Burn TC; Caulder E; Covington MB; Fridman JS; Friedman S; Katiyar K; Hollis G; Li Y; Liu C; Liu X; Marando CA; Newton R; Pan M; Scherle P; Taylor N; Vaddi K; Wasserman ZR; Wynn R; Yeleswaram S; Jalluri R; Bower M; Zhou BB; Metcalf B
J Med Chem; 2007 Feb; 50(4):603-6. PubMed ID: 17256836
[TBL] [Abstract][Full Text] [Related]
2. Design and identification of selective HER-2 sheddase inhibitors via P1' manipulation and unconventional P2' perturbations to induce a molecular metamorphosis.
Yao W; Zhuo J; Burns DM; Li YL; Qian DQ; Zhang C; He C; Xu M; Shi E; Li Y; Marando CA; Covington MB; Yang G; Liu X; Pan M; Fridman JS; Scherle P; Wasserman ZR; Hollis G; Vaddi K; Yeleswaram S; Newton R; Friedman S; Metcalf B
Bioorg Med Chem Lett; 2008 Jan; 18(1):159-63. PubMed ID: 18036818
[TBL] [Abstract][Full Text] [Related]
3. Discovery of a novel Her-1/Her-2 dual tyrosine kinase inhibitor for the treatment of Her-1 selective inhibitor-resistant non-small cell lung cancer.
Cha MY; Lee KO; Kim JW; Lee CG; Song JY; Kim YH; Lee GS; Park SB; Kim MS
J Med Chem; 2009 Nov; 52(21):6880-8. PubMed ID: 19888761
[TBL] [Abstract][Full Text] [Related]
4. Discovery and preclinical evaluation of [4-[[1-(3-fluorophenyl)methyl]-1H-indazol-5-ylamino]-5-methylpyrrolo[2,1-f][1,2,4]triazin-6-yl]carbamic acid, (3S)-3-morpholinylmethyl ester (BMS-599626), a selective and orally efficacious inhibitor of human epidermal growth factor receptor 1 and 2 kinases.
Gavai AV; Fink BE; Fairfax DJ; Martin GS; Rossiter LM; Holst CL; Kim SH; Leavitt KJ; Mastalerz H; Han WC; Norris D; Goyal B; Swaminathan S; Patel B; Mathur A; Vyas DM; Tokarski JS; Yu C; Oppenheimer S; Zhang H; Marathe P; Fargnoli J; Lee FY; Wong TW; Vite GD
J Med Chem; 2009 Nov; 52(21):6527-30. PubMed ID: 19821562
[TBL] [Abstract][Full Text] [Related]
5. Optimization of 6,7-disubstituted-4-(arylamino)quinoline-3-carbonitriles as orally active, irreversible inhibitors of human epidermal growth factor receptor-2 kinase activity.
Tsou HR; Overbeek-Klumpers EG; Hallett WA; Reich MF; Floyd MB; Johnson BD; Michalak RS; Nilakantan R; Discafani C; Golas J; Rabindran SK; Shen R; Shi X; Wang YF; Upeslacis J; Wissner A
J Med Chem; 2005 Feb; 48(4):1107-31. PubMed ID: 15715478
[TBL] [Abstract][Full Text] [Related]
6. Synergistic inhibition with a dual epidermal growth factor receptor/HER-2/neu tyrosine kinase inhibitor and a disintegrin and metalloprotease inhibitor.
Witters L; Scherle P; Friedman S; Fridman J; Caulder E; Newton R; Lipton A
Cancer Res; 2008 Sep; 68(17):7083-9. PubMed ID: 18757423
[TBL] [Abstract][Full Text] [Related]
7. Rapid development of piperidine carboxamides as potent and selective anaplastic lymphoma kinase inhibitors.
Bryan MC; Whittington DA; Doherty EM; Falsey JR; Cheng AC; Emkey R; Brake RL; Lewis RT
J Med Chem; 2012 Feb; 55(4):1698-705. PubMed ID: 22263917
[TBL] [Abstract][Full Text] [Related]
8. Antitumor activity of HKI-272, an orally active, irreversible inhibitor of the HER-2 tyrosine kinase.
Rabindran SK; Discafani CM; Rosfjord EC; Baxter M; Floyd MB; Golas J; Hallett WA; Johnson BD; Nilakantan R; Overbeek E; Reich MF; Shen R; Shi X; Tsou HR; Wang YF; Wissner A
Cancer Res; 2004 Jun; 64(11):3958-65. PubMed ID: 15173008
[TBL] [Abstract][Full Text] [Related]
9. Synthesis, biological evaluation and molecular docking studies of amide-coupled benzoic nitrogen mustard derivatives as potential antitumor agents.
Zheng QZ; Zhang F; Cheng K; Yang Y; Chen Y; Qian Y; Zhang HJ; Li HQ; Zhou CF; An SQ; Jiao QC; Zhu HL
Bioorg Med Chem; 2010 Jan; 18(2):880-6. PubMed ID: 20005116
[TBL] [Abstract][Full Text] [Related]
10. Discovery of pyrroloaminopyrazoles as novel PAK inhibitors.
Guo C; McAlpine I; Zhang J; Knighton DD; Kephart S; Johnson MC; Li H; Bouzida D; Yang A; Dong L; Marakovits J; Tikhe J; Richardson P; Guo LC; Kania R; Edwards MP; Kraynov E; Christensen J; Piraino J; Lee J; Dagostino E; Del-Carmen C; Deng YL; Smeal T; Murray BW
J Med Chem; 2012 May; 55(10):4728-39. PubMed ID: 22554206
[TBL] [Abstract][Full Text] [Related]
11. Discovery of 2-(6-{[(6-fluoroquinolin-2-yl)methyl]amino}bicyclo[3.1.0]hex-3-yl)-N-hydroxypyrimidine-5-carboxamide (CHR-3996), a class I selective orally active histone deacetylase inhibitor.
Moffat D; Patel S; Day F; Belfield A; Donald A; Rowlands M; Wibawa J; Brotherton D; Stimson L; Clark V; Owen J; Bawden L; Box G; Bone E; Mortenson P; Hardcastle A; van Meurs S; Eccles S; Raynaud F; Aherne W
J Med Chem; 2010 Dec; 53(24):8663-78. PubMed ID: 21080647
[TBL] [Abstract][Full Text] [Related]
12. Discovery of novel spiro-piperidine derivatives as highly potent and selective melanin-concentrating hormone 1 receptor antagonists.
Suzuki T; Moriya M; Sakamoto T; Suga T; Kishino H; Takahashi H; Ishikawa M; Nagai K; Imai Y; Sekino E; Ito M; Iwaasa H; Ishihara A; Tokita S; Kanatani A; Sato N; Fukami T
Bioorg Med Chem Lett; 2009 Jun; 19(11):3072-7. PubMed ID: 19403308
[TBL] [Abstract][Full Text] [Related]
13. Discovery of novel SCD1 inhibitors: 5-alkyl-4,5-dihydro-3H-spiro[1,5-benzoxazepine-2,4'-piperidine] analogs.
Uto Y; Ueno Y; Kiyotsuka Y; Miyazawa Y; Kurata H; Ogata T; Takagi T; Wakimoto S; Ohsumi J
Eur J Med Chem; 2011 May; 46(5):1892-6. PubMed ID: 21356569
[TBL] [Abstract][Full Text] [Related]
14. Remission of human breast cancer xenografts on therapy with humanized monoclonal antibody to HER-2 receptor and DNA-reactive drugs.
Pietras RJ; Pegram MD; Finn RS; Maneval DA; Slamon DJ
Oncogene; 1998 Oct; 17(17):2235-49. PubMed ID: 9811454
[TBL] [Abstract][Full Text] [Related]
15. Novel, orally bioavailable gamma-aminoamide CC chemokine receptor 2 (CCR2) antagonists.
Pasternak A; Marino D; Vicario PP; Ayala JM; Cascierri MA; Parsons W; Mills SG; Maccoss M; Yang L
J Med Chem; 2006 Aug; 49(16):4801-4. PubMed ID: 16884289
[TBL] [Abstract][Full Text] [Related]
16. Novel highly potent and selective sigma 1 receptor antagonists related to spipethiane.
Piergentili A; Amantini C; Del Bello F; Giannella M; Mattioli L; Palmery M; Perfumi M; Pigini M; Santoni G; Tucci P; Zotti M; Quaglia W
J Med Chem; 2010 Feb; 53(3):1261-9. PubMed ID: 20067271
[TBL] [Abstract][Full Text] [Related]
17. Synthesis and structure-activity relationships of 6,7-disubstituted 4-anilinoquinoline-3-carbonitriles. The design of an orally active, irreversible inhibitor of the tyrosine kinase activity of the epidermal growth factor receptor (EGFR) and the human epidermal growth factor receptor-2 (HER-2).
Wissner A; Overbeek E; Reich MF; Floyd MB; Johnson BD; Mamuya N; Rosfjord EC; Discafani C; Davis R; Shi X; Rabindran SK; Gruber BC; Ye F; Hallett WA; Nilakantan R; Shen R; Wang YF; Greenberger LM; Tsou HR
J Med Chem; 2003 Jan; 46(1):49-63. PubMed ID: 12502359
[TBL] [Abstract][Full Text] [Related]
18. Discovery of a novel class of potent and orally bioavailable sphingosine 1-phosphate receptor 1 antagonists.
Ibrahim MA; Johnson HW; Jeong JW; Lewis GL; Shi X; Noguchi RT; Williams M; Leahy JW; Nuss JM; Woolfrey J; Banica M; Bentzien F; Chou YC; Gibson A; Heald N; Lamb P; Mattheakis L; Matthews D; Shipway A; Wu X; Zhang W; Zhou S; Shankar G
J Med Chem; 2012 Feb; 55(3):1368-81. PubMed ID: 22214363
[TBL] [Abstract][Full Text] [Related]
19. Recombinant human insulin-like growth factor binding protein 3 inhibits growth of human epidermal growth factor receptor-2-overexpressing breast tumors and potentiates herceptin activity in vivo.
Jerome L; Alami N; Belanger S; Page V; Yu Q; Paterson J; Shiry L; Pegram M; Leyland-Jones B
Cancer Res; 2006 Jul; 66(14):7245-52. PubMed ID: 16849573
[TBL] [Abstract][Full Text] [Related]
20. Inhibitory effects of combinations of HER-2/neu antibody and chemotherapeutic agents used for treatment of human breast cancers.
Pegram M; Hsu S; Lewis G; Pietras R; Beryt M; Sliwkowski M; Coombs D; Baly D; Kabbinavar F; Slamon D
Oncogene; 1999 Apr; 18(13):2241-51. PubMed ID: 10327070
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
